Xphyto Therapeutics Corp
Prices are adjusted according to historical splits.
- Today's Low:
- Today's High:
- Open Price:
- 52W Low:
- 52W High:
- Prev. Close:
- Market Cap.:
- $30.85 million
- Book Value:
- Revenue TTM:
- Operating Margin TTM:
- Gross Profit TTM:
- Profit Margin:
- Return on Assets TTM:
- Return on Equity TTM:
Xphyto Therapeutics Corp had its IPO on under the ticker symbol XPHYF.
The company operates in the Healthcare sector and Pharmaceuticals industry. Xphyto Therapeutics Corp has a staff strength of 0 employees.
Shares of Xphyto Therapeutics Corp opened at $0.39 at the start of the last trading session i.e. 2023-03-24.
The stocks traded within a range of $0.39 - $0.4, and closed at $0.4.
This is a +7.99% increase from the previous day's closing price.
A total volume of 867 shares were traded at the close of the day’s session.
In the last one week, shares of Xphyto Therapeutics Corp have increased by +0.33%.
Xphyto Therapeutics Corp's Key Ratios
Xphyto Therapeutics Corp has a market cap of $30.85 million, indicating a price to book ratio of 16.0129 and a price to sales ratio of 89.8628.
In the last 12-months Xphyto Therapeutics Corp’s revenue was $419430 with a gross profit of $199478 and an EBITDA of $-9685170. The EBITDA ratio measures Xphyto Therapeutics Corp's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Xphyto Therapeutics Corp’s operating margin was -2234.54% while its return on assets stood at -66.95% with a return of equity of -397.02%.
In Q3, Xphyto Therapeutics Corp’s quarterly earnings growth was a positive 0% while revenue growth was a negative 64.4%.
Xphyto Therapeutics Corp’s PE and PEG Ratio
- Forward PE
- Trailing PE
Its diluted EPS in the last 12-months stands at $-0.179 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Xphyto Therapeutics Corp’s profitability.
Xphyto Therapeutics Corp stock is trading at a EV to sales ratio of 92.9839 and a EV to EBITDA ratio of -3.1982. Its price to sales ratio in the trailing 12-months stood at 89.8628.
Xphyto Therapeutics Corp stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $9.69 million
- Total Liabilities
- $4.40 million
- Operating Cash Flow
- Capital Expenditure
- Dividend Payout Ratio
Xphyto Therapeutics Corp ended 2023 with $9.69 million in total assets and $0 in total liabilities. Its intangible assets were valued at $9.69 million while shareholder equity stood at $3.12 million.
Xphyto Therapeutics Corp ended 2023 with $0 in deferred long-term liabilities, $4.40 million in other current liabilities, 45374826.00 in common stock, $-48315282.00 in retained earnings and $4.87 million in goodwill. Its cash balance stood at $2.19 million and cash and short-term investments were $0. The company’s total short-term debt was $0 while long-term debt stood at $1.87 million.
Xphyto Therapeutics Corp’s total current assets stands at $2.86 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $370351.00 compared to accounts payable of $153385.00 and inventory worth $180749.00.
In 2023, Xphyto Therapeutics Corp's operating cash flow was $-3858.00 while its capital expenditure stood at $3858.
Comparatively, Xphyto Therapeutics Corp paid $0 in dividends in 2023.
Other key metrics
- Current Trading Price
- 52-Week High
- 52-Week Low
- Analyst Target Price
Xphyto Therapeutics Corp stock is currently trading at $0.4 per share. It touched a 52-week high of $0.7963 and a 52-week low of $0.7963. Analysts tracking the stock have a 12-month average target price of $.
Its 50-day moving average was $0.36 and 200-day moving average was $0.39 The short ratio stood at 0 indicating a short percent outstanding of 0%.
Around 749.8% of the company’s stock are held by insiders while 0% are held by institutions.
Frequently Asked Questions About Xphyto Therapeutics Corp
Similar Industry Stocks (Pharmaceuticals)
BioNxt Solutions Inc. operates as a bioscience company in Germany, Switzerland, Austria, Israel, and Canada. It develops drug delivery methods, such as transdermal patches and oral dissolvable films designed for delivery of neurological medications; and psychedelic medicine to treat mental health-related medical conditions, including depression, anxiety, addiction, and trauma-related stress disorder. The company also develops point-of-care diagnostics comprising rapid diagnostics and biosensor screening tests for early detection and the potential for better treatment outcomes, and improved disease management; and COVID-19 PCR diagnostic kit, peri-implantitis oral biosensor, and H1N1 (swine flu) and H5N1 (avian flu) oral biosensors. In addition, it offers analytical testing and consulting services; and engages in the pathogen and oral health diagnostic and screening test, thin film drug formulation, and psychedelic pharmaceutical production and formulation businesses. The company was formerly known as XPhyto Therapeutics Corp. and changed its name to BioNxt Solutions Inc. in November 2022. BioNxt Solutions Inc. was incorporated in 2017 and is headquartered in Vancouver, Canada.